Results 31 to 40 of about 177,775 (151)

Immune Checkpoint Inhibitors in NSCLC [PDF]

Current Treatment Options in Oncology, 2014
Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson, Matthew J, Rioth, Leora, Horn   +2 more
openaire   +2 more sources

A Role of Therapy that Targets Immune Checkpoint Proteins for the Treatment of Melanoma Brain Metastasis, Liver, Breast, Pancreatic Cancer and Pancreatic Adenocarcinoma

مجله كليه طب الكندي, 2022
Checkpoint inhibitors are a type of immune therapy used to treat different types of cancers. These drugs block different checkpoint proteins, for example, CTLA-4, PD-1, and PD-L1 inhibitors.
Smaa Elsayed Mohammed, Basma Aml Youssef, Doaa Alaa Ghonai, Eman Fares Ahmed, Esraa Gharieb Mohammed, Mai Ashraf Abdo, Mai Essam Mohammed, Rana Gharieb Hassan, Reem Mohammed Mohammed, Rofida Ahmed Abd Al-Azeem, Sarah Adel Swelem, Sarah Ouda Salman, Sarah Mohammed Al-aiyq, Toka Taha Taha, Zainab Khalid Moawad   +14 more
doaj   +1 more source

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Frontiers in Pharmacology, 2023
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade.
Zherui Liu, Zherui Liu, Yun Zhu, Huan Xie, Zhengsheng Zou, Zhengsheng Zou, Zhengsheng Zou   +6 more
doaj   +1 more source

Nephrotoxicity of checkpoint inhibitors; a current challenge [PDF]

Journal of Nephropharmacology
Immune checkpoint inhibitors work by blocking the "checkpoint" mechanism that tumors use to hide from the immune system, therefore also weakening the immune system.
Samaneh Zandifar, Mahshid Imankhan, Padideh Daneii, Ali Azarpey, Leila Alem   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy

Vaccines, 2023
Hepatitis B virus (HBV) infection is the main risk factor for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high incidence and mortality worldwide.
Jin Zhang, Changwei Hu, Xiaoxiao Xie, Linzhi Qi, Chuanzhou Li, Shangze Li   +5 more
doaj   +1 more source

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Pulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica   +6 more
doaj   +1 more source

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

Kidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy, Sandra M. Herrmann, Meghan E. Sise   +2 more
doaj   +1 more source

Operative management of immune checkpoint colitis following in-transit melanoma: Case report

Frontiers in Oncology, 2023
Immune checkpoint inhibitors are increasingly used as powerful anti-neoplastic therapies in the setting of melanoma. Colitis is a known complication of immune checkpoint inhibitors that if often medically managed.
Betzaira G. Childers, Eileen Donovan, Winifred M. Lo, Lauren M. Janowak, Jeffrey Sussman, Christopher F. Janowak   +5 more
doaj   +1 more source

Research Progress of Immune Checkpoint Inhibitors in Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2020
Tumor immunity is a new line of research for the treatment of patients with solid tumors, and negative regulators of the immune system called immune checkpoints play a key role in limiting antitumor immunologic responses.
ZHUANG Yuwen, SHEN Junyi, LIU Shenlin, CAI Hui   +3 more
doaj   +1 more source

Research Progress of Immune Checkpoint Therapy on Colorectal Cancer

Zhongliu Fangzhi Yanjiu, 2021
At present, immunotherapy is in full swing in the treatment of non-small cell lung cancer, melanoma, bladder cancer and other tumor species, and its treatment methods are also diverse, including tumor vaccine treatment, adoptive T cell therapy, immune ...
CAO Qihua, XU Yanbo, XU Dong
doaj   +1 more source